| Sep 3 |
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
|
| Aug 12 |
Caribou Biosciences appoints Albertson as CMO
|
| Aug 12 |
Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
|
| Aug 8 |
Caribou Biosciences Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 6 |
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 6 |
Caribou Bioscience GAAP EPS of -$0.42 beats by $0.04, revenue of $3.46M beats by $0.42M
|
| Aug 6 |
Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 6 |
Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
|
| Jul 17 |
Caribou cuts 12% of workforce, extends cash runway into 2H 2026
|
| Jul 17 |
Caribou lays off staff; Roche walks away from Relay
|
